The promise of new drugs for schizophrenia treatment

被引:44
作者
Tamminga, CA
机构
[1] Department of Psychiatry, Univ. of Maryland School of Medicine, Baltimore, MD
[2] Maryland Psychiatric Research Center, Baltimore, MD 21228
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 1997年 / 42卷 / 03期
关键词
new antipsychotic; schizophrenia; clozapine; risperidone; olanzapine; sertindole; efficacy; side-effects;
D O I
10.1177/070674379704200304
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions. Method: Review of the relevant literature and publicly presented data. Results: Traditional neuroleptics have considerable effectiveness in treating positive symptoms of psychosis but can cause serious motor side effects. Clozapine produces no motor side effects and delivers a unique antipsychotic action. Risperidone also produces low motor side effects, but only at relatively low doses. Olanzapine and sertindole are newly introduced. Both have potent antipsychotic actions, with greatly reduced motor side effects. Both drugs also have possible advantages in negative symptoms. Conclusions: These data support the conclusion that several new antipsychotics ave becoming available for general use which are safe and effective in the treatment of psychosis and have sever-al advantages over traditional neuroleptics.
引用
收藏
页码:265 / 273
页数:9
相关论文
共 75 条
[1]  
[Anonymous], 1952, C MED AL NEUR FRANC
[2]   IMPORTANCE OF PHARMACOLOGICAL CONTROL IN PET STUDIES - EFFECTS OF THIOTHIXENE AND HALOPERIDOL ON CEREBRAL GLUCOSE-UTILIZATION IN CHRONIC-SCHIZOPHRENIA [J].
BARTLETT, EJ ;
WOLKIN, A ;
BRODIE, JD ;
LASKA, EM ;
WOLF, AP ;
SANFILIPO, M .
PSYCHIATRY RESEARCH-NEUROIMAGING, 1991, 40 (02) :115-124
[3]   Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].
Beasley, CM ;
Sanger, T ;
Satterlee, W ;
Tollefson, G ;
Tran, P ;
Hamilton, S ;
Green, A ;
Dott, S ;
Pfister, G ;
Roxas, L ;
Small, J ;
Thomas, M ;
Ames, D ;
Schooler, N ;
Baker, R ;
Levine, R ;
Fabre, L ;
Friedel, R ;
Safferman, A ;
Lieberman, J ;
Stahl, S .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167
[4]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[5]  
BECK PE, 1996, J NEW DEV CLIN MED, V14, P63
[6]  
BERSANI G, 1986, CURR THER RES CLIN E, V40, P492
[7]  
BOGESO KP, 1995, ALFRED BENZON SYMP S, V38, P361
[8]  
BORISON RL, 1992, PSYCHOPHARMACOL BULL, V28, P213
[9]  
BORISON RL, 1996, CLIN PSYCHOPHARMACOL, V16, P158
[10]   CLONING AND EXPRESSION OF A RAT D2 DOPAMINE RECEPTOR CDNA [J].
BUNZOW, JR ;
VANTOL, HHM ;
GRANDY, DK ;
ALBERT, P ;
SALON, J ;
CHRISTIE, MJ ;
MACHIDA, CA ;
NEVE, KA ;
CIVELLI, O .
NATURE, 1988, 336 (6201) :783-787